MI
IBRX icon

Markowski Investments’s ImmunityBio IBRX Stock Holding History

Markowski Investments’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29K Buy
+3,307
New +$25K 0.01% 270

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Markowski Investments's IBRX Position: Q2 2026 in Review

Markowski Investments opened a new position in ImmunityBio (IBRX) in Q2 2026: 3,307 shares worth $29K. The stake represents 0.01% of the portfolio and ranks #270 among its holdings.

314 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Markowski Investments held 3,307 shares of ImmunityBio worth $29K as of Q2 2026.
  • ImmunityBio was a new Markowski Investments position in Q2 2026.
  • ImmunityBio made up 0.01% of Markowski Investments's portfolio in Q2 2026, its #270 holding.
  • 314 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Markowski Investments's 13F filing for Q2 2026, filed 13 Aug 2026.